![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Fierce Pharma Biopharma News & Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
2024 approvals: Biopharma delivered 55 new drugs, biologics
The FDA signed off on 55 new drugs in 2024, down from 60-plus in 2023.
Pfizer, BMS and more start 2025 with drug price hikes: report
Jan 2, 2025 · But, while the number of drugs becoming more costly is going up, the median scale of drug price increases has fallen significantly over the past decade, from 9% in 2015 to 4.5% in 2024, Reuters ...
Trump won a second term. What does it mean for biopharma?
Nov 6, 2024 · On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed to win the U.S. | Over his first term, Donald Trump advocated for ...
Lilly seeks to intervene in compounded tirzepatide lawsuit
Jan 2, 2025 · After a compounding group sued the FDA over its decision to declare the shortage of tirzepatide over, Eli Lilly is looking to muscle in on the case.
Top 20 pharma companies by 2023 revenue - Fierce Pharma
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing ...
Top 10 most anticipated drug launches of 2024 | Fierce Pharma
Every year, we tap Evaluate's annual preview report to assess the biggest potential new drugs of the year ahead. Typically, major pharmaceutical and biotechnology companies are featured, each ...
Catalyst settles with Teva, staving off Firdapse generic until 2035
Jan 9, 2025 · Prior to filing its lawsuit, Catalyst in January of 2023 revealed that Teva had filed for approval of a generic version of Firdapse. Notably, the Israeli-American pharma said it planned to market ...
FDA requires Pfizer, GSK to add warning on label of RSV shots
Jan 8, 2025 · In October, Pfizer reported a 5% year-over-year downturn in its third-quarter sales of Abrysvo. In 2023, the shot racked up (PDF) $890 million.. Earlier this week—in a letter to shareholders ...
Where is the industry going with its rush to radiopharma?
Jan 10, 2025 · In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry. Novartis paid $1 billion for Mariana Oncology. Eli Lilly jumped in with ...